Kailera Therapeutics’ IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue.

The post Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity Drugs appeared first on MedCity News.

Consumers are inundated with false information circulating online about GLP-1 medicines, which causes confusion and can lead to potentially serious health problems resulting from dosing errors and adverse reactions to ingredients in compounded GLP-1 products.

The post It’s Time to Put Guardrails on GLP-1 Compounding appeared first on MedCity News.

FDA approval for Eli Lilly’s oral GLP-1 drug, Foundayo, comes about three months after Novo Nordisk launched its Wegovy pill. While clinical trial results for both daily pills showed comparable weight reduction, Lilly’s pill offers patients a slight dosing advantage.

The post Eli Lilly Gets Speedy FDA Nod for Oral GLP-1 Drug, a Competitor to New Novo Nordisk Pill appeared first on MedCity News.

Structure Therapeutics’ aleniglipron, a once-daily oral GLP-1 drug, led to an average 16% weight loss measured at 44 weeks. Based on these results, the biotech is preparing for Phase 3 testing expected to begin in the second half of this year.

The post Structure Therapeutics Oral GLP-1 Obesity Drug Achieves ‘Injectable-Like Efficacy’ in Phase 2 Test appeared first on MedCity News.

Mark Cuban, co-founder of Cost Plus Drugs, and Linda Yaccarino, CEO of the employer GLP-1 platform eMed Population Health, were at SXSW drawing a contrast between their approach to GLP-1 drugs and that of other direct-to-consumer companies. They also announced a collaboration where Cost Plus Drugs will be one of eMed’s distribution partners.

The post At SXSW, Cuban and eMed CEO Draw Contrast Between Them and Other “Marketing” Companies appeared first on MedCity News.

Jake Leach became DexCom’s chief executive on January 1 and is trying to write the turnaround story of this innovative medtech company. One story to tell is how CGMs should be a no-brainer for type 2 diabetes patients on GLP-1 weight loss drugs.

The post DexCom’s CEO Believes Diabetics On GLP-1s Should Also Wear CGMs appeared first on MedCity News.

Preliminary Phase 2 data show Roche’s CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity.

The post Roche Obesity Drug’s Phase 2 Results Are Competitive, But True Test May Come From Combo Studies appeared first on MedCity News.

We have to cover medical nutrition therapy for those who need it most, including Medicare beneficiaries. Almost all commercial payers are already doing this – the government needs to catch up.

The post Medicare Is Covering GLP-1s – It’s Time to Cover the Care That Makes Them Sustainable appeared first on MedCity News.

The same forces now at play in medical aesthetics will soon appear in every therapeutic category where treatment overlaps with identity, from hormones to nootropics to genetic optimization.

The post The GLP-1 Revolution: Medical Aesthetics And The Coming Battle For Control appeared first on MedCity News.

The weight loss market is at yet another inflection point. The euphoria of the past three years is now confronting the realities of how obesity medications will scale to address an epidemic that impacts over 1 billion people globally.

The post The Weight Loss Market in 2026: 3 Questions That Will Shape the Next Decade appeared first on MedCity News.

Microdosing won’t be the right choice for everyone. But for many patients, it’s already proving to be the difference between quitting obesity treatment early and making lasting progress.

The post What if Less Can Be More? A New Approach to GLP-1 Weight Loss Medications appeared first on MedCity News.

Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.

The post Novo Nordisk’s Wegovy Pill Becomes First FDA-Approved Oral GLP-1 Drug for Weight Loss appeared first on MedCity News.

The high dose of Eli Lilly’s retatrutide led to an average 28.7% loss in body weight measured at 68 weeks. These Phase 3 results are the first from the experimental obesity drug’s broad clinical trial program, which is on track to yield seven data readouts in the coming year.

The post Eli Lilly Drug for 3 Obesity Targets Sets New High Bar for Weight Loss in a Clinical Trial appeared first on MedCity News.

YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations.

The post Pfizer’s Appetite for More Obesity Meds Leads to $150M Deal for Oral GLP-1 Drug From China appeared first on MedCity News.

Instead of viewing obesity as one uniform condition, experts now recognize that it can arise from multiple biological patterns. Understanding that difference could finally change how we approach treatment altogether. 

The post It’s the End Of the Line for One‑Size‑Fits‑All Weight Loss appeared first on MedCity News.

What are the alternatives to extending ACA subsidies for the 22 million people who purchase health plans on the ACA Marketplace? That’s the focus of the latest episode of the Debunked podcast, hosted by MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch.

The post Debunked Episode 22: With ACA Subsidies Set to Expire and the Open Enrollment Window Closing, Members of Congress Brainstorm Alternatives appeared first on MedCity News.

MedCity News Editor in Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch, also discussed whether bitcoin would play a greater role in healthcare deals and the Trump administration’s mixed messages on autism and Tylenol.

The post Debunked Episode 20: A Look at H-1B Visas in Healthcare, M&A Deals for Bitcoin and More appeared first on MedCity News.

With the global market for anti-obesity drugs projected to hit $95 billion by 2030, it’s no surprise that compounded semaglutide is gaining traction as a cheaper, more accessible option. But for all its appeal, this route comes with real risks: regulatory uncertainty, legal exposure, and major insurance hurdles.

The post Protecting Your Biotech: Understanding the Risks of Compounded GLP-1s appeared first on MedCity News.

GLP-1s have real value, but not all people respond to them the same way. The real question isn’t just what these drugs cost, but who they’re working for — and our healthcare system doesn’t have a reliable way to reconcile the two.  

The post America Is Betting Big On GLP-1s. It Doesn’t Have To Be A Gamble appeared first on MedCity News.

Viking Therapeutics’ obesity pill met weight reduction goals of its Phase 2 test, but gastrointestinal side effects led to high discontinuation rates. Even so, analysts see potential for a lower dose of the Viking drug as a maintenance therapy.

The post Side Effects Make Viking’s Oral Obesity Drug a Tough Pill for Investors to Swallow appeared first on MedCity News.

Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s room for many MASH drugs with the treatment landscape expected to shape up to include combinations of therapies bringing different approaches to this fatty liver disease.

The post FDA Approval Expands Novo Nordisk’s Wegovy to the Fatty Liver Disease MASH appeared first on MedCity News.

Here are five guidelines to help employers balance health outcomes and financial responsibility to ensure that GLP-1 coverage is effective, affordable, and aligned with improved health and workforce well-being for employees and their families.

The post How Employers Can Build an Effective GLP-1 Strategy appeared first on MedCity News.

[Sponsored] The 2025 Benefits Sentiment Index, a survey of 120 benefit consultants to self-insured employers, focuses on healthcare navigation, GLP-1 drug coverage and AI trends for healthcare benefits.

The post Healthcare Benefit Trends Report: Employers Shift to More Independent Navigation, Embrace GLP-1 Drugs with Restrictions appeared first on MedCity News.

Employers have a unique opportunity to shift from reactive to proactive care, in an unprecedented way. By grounding benefits strategies in clinical innovation and time-tested behavior change, healthy aging and enhanced quality of life is more achievable than ever before.

The post The Future Of Chronic Condition Management: Living Better For Longer appeared first on MedCity News.

As scientists and researchers figure out the right balance of GLP-1 to glucagon ratio and a better drug delivery method, we are beginning to turn the page for the many individuals suffering from obesity.

The post Turning the Page for Obesity Therapies — Addressing Tolerability and Delivery appeared first on MedCity News.

The Phase 3 results in China are encouraging for Kailera Therapeutics, which holds rights to the molecule in the rest of the world. The startup is preparing a global clinical development program for this drug, a once-weekly injectable GLP-1 and GIP receptor agonist.

The post Hengrui Pharma’s Potential Rival to El Lilly’s Zepbound Leads to 18% Weight Loss in Key Study appeared first on MedCity News.

This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.

The post GLP-1s, Personalization, and Big Pharma Power Plays: What’s Really at Stake in the Eli Lilly Lawsuit  appeared first on MedCity News.

GLP-1s are a breakthrough, but they are not the end of the story. To ensure lasting success, we must pair pharmacological interventions with behavioral support, personalized data, and continuous guidance.

The post Beyond the Prescription: Supporting Long-Term Metabolic Health After GLP-1s appeared first on MedCity News.

Novo Nordisk, AbbVie, and Roche each have weekly injectable drug candidates designed to bind to and activate the amylin receptor to trigger weight loss. Metsera’s contender, MET-233i, is designed with technology that enables longer dosing intervals and the company is proceeding with development of this engineered peptide as a monotherapy and as part of a drug combination.

The post Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med appeared first on MedCity News.

Healthcare and benefits leaders must step up to provide menopausal women with the full-spectrum care they need to protect musculoskeletal and metabolic health for lifelong strength and well-being.

The post Menopausal Women Deserve Better Obesity Care appeared first on MedCity News.